Drugs / DTaP-HB-IPV
DTaP-HB-IPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02610348 | Nov → Dec 2015 | hepatitis B virus infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-HB-IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02610348 ↗ |
| Known as | DTaP-IPV-HB/PRP∼T | “DTaP-IPV-HB-PRP∼T (Hexaxim™) or DTaP-IPV-HB/PRP∼T (Infanrix hexa™)” PMID 29333947 ↗ Feb 2018 |
| Known as | Infanrix Hexa | “DTaP-IPV-HB-Hib hexavalent vaccine (Hexaxim® or Infanrix Hexa®)” NCT02610348 ↗ |
| Modality | Vaccine | “three-dose infant primary series vaccination” NCT02610348 ↗ |